Since Urovant Sciences Ltd. (NASDAQ:UROV) and Odonate Therapeutics Inc. (NASDAQ:ODT) are part of the Biotechnology industry, they are influenced by contrast. Net Margins Return on Equity Return on Assets Urovant Sciences Ltd. 49,952,606.64% -176.5% -118.3% Odonate Therapeutics Inc. 41,828,087.17% -75.2% -65.3%LiquidityThe Current Ratio and Quick Ratio of Urovant Sciences Ltd. are 6.6 and 6.6 respectively. Odonate Therapeutics Inc. can pay off short and long-term obligations better than Urovant Sciences Ltd.Analyst RecommendationsUrovant Sciences Ltd. and Odonate Therapeutics Inc. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Urovant Sciences Ltd. 12.92% 21.99% 19.7% 49.94% 83.6% 93.63% Odonate Therapeutics Inc. -9.8% 0.13% 1.11% 24.64% 112.98% 120.24%For the past year Urovant Sciences Ltd.’s stock price has smaller growth than Odonate Therapeutics Inc.SummaryOdonate Therapeutics Inc. beats Urovant Sciences Ltd. on 7 of the 10 factors. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States.

Source: Otago Daily Times December 14, 2019 05:54 UTC